A large Danish study of nearly 78,000 adults has revealed that half of those who begin taking semaglutide for weight loss abandon the treatment within a year — a pattern researchers describe as deeply troubling, given that the drug's benefits dissolve the moment it is stopped. The findings, presented in Vienna at a major diabetes conference, expose not merely a question of willpower or side effects, but a structural inequality: the drug costs roughly €2,000 annually, and those with the least means are the most likely to walk away. In this, semaglutide becomes a mirror held up to a broader huma
NDTV Profit
· Sep 15, 2025
· health
· 2 min de leitura
High
Apuração: Verificado
Half of Semaglutide Users Quit Within a Year, Study Warns Against Quick-Fix Mentality
◉
Health & Medicine
8412 artigos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% correspondência
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% correspondência
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% correspondência
Cobertura Relacionada
BBC News · Aug 25
School asbestos exposure linked to woman's death at 46, family claims
A woman died from mesothelioma at 46, likely exposed to asbestos at her Cardiff school decades earlier. Her family is su…
Future of Personal Health - · Aug 25 NGS Technology Transforms Uncertain Infections Into Actionable DiagnosesHybrid-capture NGS technology helps clinicians identify pathogens in diagnostically challenging cases by simultaneously …
The Guardian · Aug 25 Shark attack survivor Leah Stewart recalls 'monster' in first interview since losing armLeah Stewart, who lost her arm in a June shark attack at Coogee Beach, recalls the traumatic encounter in her first inte…
Education News Canada · Aug 25 Systemic racism, restrictive policies block Black Canadians from blood donationBlack Canadians face systemic barriers to blood donation despite critical need for ethnicity-matched blood for sickle ce…
Viés e Enquadramento
⚖
Article presents study findings on semaglutide discontinuation with cautionary framing, emphasizing researcher warnings and socioeconomic disparities without significant bias.
Bias Direction
center-left
Confidence
MED
Problem-focused framing that emphasizes discontinuation rates, researcher warnings against 'quick-fix mentality,' and socioeconomic inequities. The headline and structure prioritize concerns over benefits.
quick-fix mentality
disturbing trend
concerns about fairness
marginalised groups
major barrier
Pharmaceutical company or manufacturer response/perspective
Healthcare providers' views on discontinuation rates and patient management strategies
Positive outcomes or success stories from long-term users
Economic benefits or cost-effectiveness analyses
Patient perspectives on why they discontinued (beyond cost implications)
Impacto Geopolítico
🌎
Semaglutide discontinuation study reveals healthcare access disparities by income/age, with geopolitical implications for pharmaceutical equity and global health policy.
Escalation Risk
low
Confidence
MED
European Union
Denmark
United States
Global pharmaceutical markets
Wealthy nations and high-income populations gain preferential access to expensive GLP-1 drugs, widening health inequality gaps. Pharmaceutical companies maintain pricing power while lower-income groups face treatment barriers, reinforcing existing socioeconomic disparities in healthcare outcomes across developed nations.
Similar to insulin access disparities post-discovery (1921), where wealthy populations benefited while poor communities faced exclusion, creating long-term health equity debates that persist today.
Lente Econômica
📈
50% of semaglutide users discontinue within a year, revealing affordability barriers and unrealistic expectations that threaten the weight-loss drug market's sustainability and profitability.
Market Signal
bearish
Confidence
HIGH
Pharmaceutical/Biotechnology
Healthcare Services
Health Insurance
Medical Device Manufacturing
Wellness Industry
High discontinuation rates indicate consumers face affordability challenges (~€2,000/year) and may experience weight regain post-treatment. Lower-income households are disproportionately excluded, widening health inequality. Younger users' higher dropout rates suggest unrealistic expectations about long-term commitment.
Governments may face pressure to regulate pricing, expand insurance coverage, or mandate affordability programs. Healthcare systems must address equity gaps in access. Regulators may require clearer labeling about long-term treatment necessity. Public health campaigns needed to counter 'quick-fix' misconceptions.